Latest News and Press Releases

LONDON, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Former award-winning Made in Chelsea star Stevie Johnson is to host a new podcast series which delves into the careers of inspirational content creators to...

LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- High-flying influencer marketing agency, Disrupt, has been selected by Wizz Air, Europe's fastest growing and the world’s most environmentally sustainable...

YONKERS, N.Y., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...

YONKERS, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...

Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021 BARDA contract award provides up to $86.8 million for exebacase...

YONKERS, N.Y., March 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...

BARDA to provide funding for the ongoing Phase 3 DISRUPT study of exebacase for the treatment of patients with Staph aureus bloodstream infections Results from the Phase 3 DISRUPT study interim...

Exebacase Phase 2 study results published in the Journal of Clinical Investigation Continued patient enrollment in ongoing Phase 3 DISRUPT study of exebacase Successful public equity offering,...

Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia Exebacase Phase...

YONKERS, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...